Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CA3 | P07451 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1317863 | 0.69 | GSK3A (0.40) | CA9CA12LMNAMCL1TDP1 | |
| SCHEMBL28402894 | 0.68 | HPGD (0.37) | LMNAALDH1A1 | |
| SCHEMBL8487842 | 0.68 | CA1 (0.32) | CA1CA9CA12CA2LMNA | |
| SCHEMBL13474023 | 0.65 | TDP1 (0.31) | TDP1 | |
| SCHEMBL8666055 | 0.63 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL14207200 | 0.63 | — | — | |
| SCHEMBL2525091 | 0.61 | FFAR4 (0.31) | — | |
| SCHEMBL6938317 | 0.60 | ALDH1A1 (0.31) | CA1CA9ALDH1A1 | |
| SCHEMBL6822041 | 0.60 | ALDH1A1 (0.40) | CA1CA9CA12CA2LMNA | |
| SCHEMBL18602818 | 0.59 | CA1 (0.34) | CA1CA9LMNAALDH1A1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111888353-A | Application of daphnetin in preparation of medicine for preventing and/or treating muscular atrophy, sarcopenia and hypokinesia caused by aging | 西安交通大学 | 2020-11-06 | — | — | CN | disclosed |
| EP-3415494-B1 | MONOMER, POLYMER, RESIST COMPOSITION, AND PATTERNING PROCESS | SHINETSU CHEMICAL CO (JP) | 2019-10-30 | — | — | EP | disclosed |
| EP-3205640-B1 | MONOMER, POLYMER, RESIST COMPOSITION, AND PATTERNING PROCESS | SHINETSU CHEMICAL CO (JP) | 2019-05-22 | — | — | EP | disclosed |
| EP-3035121-B1 | MONOMER, POLYMER, RESIST COMPOSITION, AND PATTERNING PROCESS | SHINETSU CHEMICAL CO (JP) | 2019-03-13 | — | — | EP | disclosed |
| EP-3168207-B1 | MONOMER, POLYMER, RESIST COMPOSITION, AND PATTERNING PROCESS | SHINETSU CHEMICAL CO (JP) | 2019-02-06 | — | — | EP | disclosed |
| EP-3205640-A1 | MONOMER, POLYMER, RESIST COMPOSITION, AND PATTERNING PROCESS | Shin-Etsu Chemical Co., Ltd. (JP) | 2017-08-16 | — | — | EP | disclosed |
| EP-3168207-A1 | MONOMER, POLYMER, RESIST COMPOSITION, AND PATTERNING PROCESS | Shin-Etsu Chemical Co., Ltd. (JP) | 2017-05-17 | — | — | EP | disclosed |
| EP-2993520-B1 | RESIST COMPOSITION AND PATTERNING PROCESS | SHINETSU CHEMICAL CO (JP) | 2017-03-08 | — | — | EP | disclosed |
| EP-2450038-A1 | A PHARMACEUTICAL COMPOSITION FOR TREATING DIABETIC NEPHROPATHY AND THE PREPARATION METHOD AND USE THEREOF | Guangzhou Consun Medicine R&D Co., Ltd. (CN) | 2012-05-09 | — | — | EP | disclosed |
| US-20100267819-A1 | PHARMACEUTICAL COMPOSITION FOR DIABETIC NEPHROPATHY AND ITS PREPARATION AND APPLICATION | Guangzhou Consun Medicine R&D Medicine (CN) | 2010-10-21 | — | — | US | disclosed |
| CN-1594304-A | Process for preparation of 7,8-dihydrocoumarin included by cyclodextrin and its derivatives | JILIN XIDIAN PHARMACEUTICAL TE (CN) | 2005-03-16 | — | — | CN | disclosed |
| CN-1594304-A | Process for preparation of 7,8-dihydrocoumarin included by cyclodextrin and its derivatives | JILIN XIDIAN PHARMACEUTICAL TE (CN) | 2005-03-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267819-A1 | PHARMACEUTICAL COMPOSITION FOR DIABETIC NEPHROPATHY AND ITS PREPARATION AND APPLICATION | REN, ATP6V1B1, CYP2A7 | CA1 4591/4885CA9 1737/4885CA12 4003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.